Literature DB >> 26365387

Protein microarrays identify disease-specific anti-cytokine autoantibody profiles in the landscape of immunodeficiency.

Jacob M Rosenberg1, Jordan V Price2, Gabriela Barcenas-Morales3, Lourdes Ceron-Gutierrez4, Sophie Davies4, Dinakantha S Kumararatne4, Rainer Döffinger5, Paul J Utz6.   

Abstract

BACKGROUND: Anti-cytokine autoantibodies (ACAAs) are pathogenic in a handful of rare immunodeficiencies. However, the prevalence and significance of other ACAAs across immunodeficiencies have not yet been described.
OBJECTIVE: We profiled ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and assessed the sensitivity and specificity of protein microarrays for ACAA identification and discovery.
METHODS: Highly multiplexed protein microarrays were designed and fabricated. Blinded serum samples from a cohort of 58 immunodeficiency patients and healthy control subjects were used to probe microarrays. Unsupervised hierarchical clustering was used to identify clusters of reactivity, and after unblinding, significance analysis of microarrays was used to identify disease-specific autoantibodies. A bead-based assay was used to validate protein microarray results. Blocking activity of serum containing ACAAs was measured in vitro.
RESULTS: Protein microarrays were highly sensitive and specific for the detection of ACAAs in patients with autoimmune polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent with those reported in the published literature. Protein microarray results were validated by using an independent bead-based assay. To confirm the functional significance of these ACAAs, we tested and confirmed the blocking activity of select ACAAs in vitro.
CONCLUSION: Protein microarrays are a powerful tool for ACAA detection and discovery, and they hold promise as a diagnostic for the evaluation and monitoring of clinical immunodeficiency.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-cytokine autoantibodies; autoimmune polyendocrine syndrome type I; immunodeficiency; protein microarray; pulmonary alveolar proteinosis; thymoma

Mesh:

Substances:

Year:  2015        PMID: 26365387      PMCID: PMC4715746          DOI: 10.1016/j.jaci.2015.07.032

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  45 in total

1.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors:  Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

Review 2.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

3.  Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli.

Authors:  Darragh Duffy; Vincent Rouilly; Valentina Libri; Milena Hasan; Benoit Beitz; Mikael David; Alejandra Urrutia; Aurélie Bisiaux; Samuel T Labrie; Annick Dubois; Ivo G Boneca; Cécile Delval; Stéphanie Thomas; Lars Rogge; Manfred Schmolz; Lluis Quintana-Murci; Matthew L Albert
Journal:  Immunity       Date:  2014-03-20       Impact factor: 31.745

4.  Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study.

Authors:  P Ghillani; C André; C Toly; A M Rouquette; D Bengoufa; P Nicaise; C Goulvestre; A Gleizes; M A Dragon-Durey; M A Alyanakian; P Chretien; S Chollet-Martin; L Musset; B Weill; C Johanet
Journal:  Autoimmun Rev       Date:  2011-04-05       Impact factor: 9.754

5.  Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.

Authors:  U Dirksen; R Nishinakamura; P Groneck; U Hattenhorst; L Nogee; R Murray; S Burdach
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis.

Authors:  Kanji Uchida; David C Beck; Takashi Yamamoto; Pierre-Yves Berclaz; Shuichi Abe; Margaret K Staudt; Brenna C Carey; Marie-Dominique Filippi; Susan E Wert; Lee A Denson; Jonathan T Puchalski; Diane M Hauck; Bruce C Trapnell
Journal:  N Engl J Med       Date:  2007-02-08       Impact factor: 91.245

7.  Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis.

Authors:  Takuro Sakagami; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Robert E Wood; Susan E Wert; Jeffrey A Whitsett; Bruce C Trapnell; Maurizio Luisetti
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

8.  Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis.

Authors:  Anagha Malur; Mani S Kavuru; Irene Marshall; Barbara P Barna; Isham Huizar; Reema Karnekar; Mary Jane Thomassen
Journal:  Respir Res       Date:  2012-06-14

9.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

View more
  5 in total

1.  Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies.

Authors:  Tiffany Perkins; Jacob M Rosenberg; Carole Le Coz; Joseph T Alaimo; Melissa Trofa; Sureni V Mullegama; Richard J Antaya; Soma Jyonouchi; Sarah H Elsea; Paul J Utz; Eric Meffre; Neil Romberg
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

2.  Prevalence and correlation of cytokine-specific autoantibodies with epidemiological factors and C-reactive protein in 8,972 healthy individuals: Results from the Danish Blood Donor Study.

Authors:  Jakob Hjorth von Stemann; Andreas Stribolt Rigas; Lise Wegner Thørner; Daniel Guldager Kring Rasmussen; Ole Birger Pedersen; Klaus Rostgaard; Christian Erikstrup; Henrik Ullum; Morten Bagge Hansen
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

3.  Anticytokine autoantibodies leading to infection: early recognition, diagnosis and treatment options.

Authors:  Gabriela Barcenas-Morales; Paulina Cortes-Acevedo; Rainer Doffinger
Journal:  Curr Opin Infect Dis       Date:  2019-08       Impact factor: 4.915

4.  IL-6-specific autoantibodies among APECED and thymoma patients.

Authors:  Jaanika Kärner; Maire Pihlap; Annamari Ranki; Kai Krohn; Katarina Trebusak Podkrajsek; Nina Bratanic; Tadej Battelino; Nick Willcox; Pärt Peterson; Kai Kisand
Journal:  Immun Inflamm Dis       Date:  2016-05-25

5.  Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes.

Authors:  Elena N Savvateeva; Marina Yu Yukina; Nurana F Nuralieva; Marina A Filippova; Dmitry A Gryadunov; Ekaterina A Troshina
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.